Quest Diagnostics (DGX) Stock Forecast & Price Target

$145.59

+1.34 (+0.93%)

(As of 07/26/2024 ET)

Quest Diagnostics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 13 Analyst Ratings

Based on 13 Wall Street analysts who have issued ratings for Quest Diagnostics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 9 have given a hold rating, and 4 have given a buy rating for DGX.

Consensus Price Target

$149.38
2.61% Upside

High Forecast	$165.00
Average Forecast	$149.38
Low Forecast	$130.00

According to the 13 analysts' twelve-month price targets for Quest Diagnostics, the average price target is $149.38. The highest price target for DGX is $165.00, while the lowest price target for DGX is $130.00. The average price target represents a forecasted upside of 2.61% from the current price of $145.59.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)
Hold	9 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$149.38	$146.67	$146.17	$151.20
Forecasted Upside	2.61% Upside	9.15% Upside	9.05% Upside	6.70% Upside

Get Quest Diagnostics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

Ad Porter & Company

Obama wins Presidential debate

When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.”

Please, watch this now before it’s too late.

DGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Quest Diagnostics Stock vs. The Competition

Type	Quest Diagnostics	Medical Companies	S&P 500
Consensus Rating Score	2.31	2.72	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	2.89% Upside	2,827.22% Upside	9.48% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/24/2024	Robert W. Baird 2 of 5 stars		Boost Target	Neutral ➝ Neutral	$153.00 ➝ $154.00	+6.93%
7/15/2024	Truist Financial 1 of 5 stars		Boost Target	Hold ➝ Hold	$150.00 ➝ $158.00	+9.09%
7/10/2024	Citigroup 3 of 5 stars	P. Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$145.00 ➝ $165.00	+19.25%
5/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$152.00 ➝ $155.00	+11.64%
4/25/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$138.00 ➝ $144.00	+6.82%
4/24/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$139.00 ➝ $146.00	+5.96%
Get the Latest News and Ratings for DGX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.
4/24/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$150.00 ➝ $155.00	+13.35%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
2/26/2024	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$135.00	+6.23%
2/7/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$140.00 ➝ $155.00	+22.76%
12/12/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$140.00 ➝ $160.00	+16.82%
11/6/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$130.00 ➝ $140.00	+4.09%
10/11/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$136.00 ➝ $130.00	+5.03%
8/3/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight ➝ Equal Weight	$145.00	+6.35%
2/3/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight	$135.00 ➝ $140.00	-0.44%
1/25/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$143.00 ➝ $146.00	+0.75%
10/21/2022	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold	$129.00 ➝ $140.00	+3.97%
10/20/2022	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Brackmann Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:35 PM ET.

DGX Forecast - Frequently Asked Questions

What is Quest Diagnostics' forecast for 2024?: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Quest Diagnostics is $149.38, with a high forecast of $165.00 and a low forecast of $130.00.
Should I buy or sell Quest Diagnostics stock right now?: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DGX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
Does Quest Diagnostics's stock price have much upside?: According to analysts, Quest Diagnostics's stock has a predicted upside of 9.94% based on their 12-month stock forecasts.
Has Quest Diagnostics been upgraded by Wall Street analysts recently?: Over the previous 90 days, Quest Diagnostics's stock had 1 upgrade by analysts.
What analysts cover Quest Diagnostics?: Quest Diagnostics has been rated by research analysts at Citigroup, JPMorgan Chase & Co., Robert W. Baird, and Truist Financial in the past 90 days.
Do Wall Street analysts like Quest Diagnostics more than its competitors?: Analysts like Quest Diagnostics less than other "medical" companies. The consensus rating for Quest Diagnostics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DGX compares to other companies.